Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Promises RWD Guidance In Plan To Boost Trial Innovation

Executive Summary

The UK medicines regulator has published a new plan to deliver on several short-term projects as it tries to keep pace with the fast-moving life sciences sector and the needs of patients. 

You may also be interested in...



England To Get ‘First Ever’ Patient Safety Commissioner Next Year

The UK government has revealed a number of changes it is making to the health care system in response to a report that found serious lapses regarding the safety of patients who were using certain treatments. 

UK Reveals Plan To Improve Access To Safe New Medicines

The three-year Delivery Plan just unveiled by the UK medicines agency is part of its aim to create a “new era” in drug regulation.

UK Focuses On Recovering Non-COVID-19 Research

The UK government has set aside over £64m ($89m) to support the first phase of activities to be undertaken in the coming months under a two-part initiative to strengthen clinical research delivery.

Related Content

Topics

UsernamePublicRestriction

Register

PS144585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel